An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.

@article{Giembycz2006AnUA,
  title={An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.},
  author={Mark A. Giembycz},
  journal={British journal of clinical pharmacology},
  year={2006},
  volume={62 2},
  pages={138-52}
}
Cilomilast (Ariflo, SB 207499) is an orally active, second-generation phosphodiesterase (PDE) 4 inhibitor that is being developed by GlaxoSmithkline for the treatment of chronic obstructive pulmonary disease (COPD). The results of Phase I and Phase II studies have demonstrated that cilomilast significantly improves lung function and quality of life to a clinically meaningful extent, which has led to a comprehensive Phase III programme of research evaluating efficacy, safety and mechanism of… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

Similar Papers

Loading similar papers…